GlassScriptPhysician profile
Thomas A Pechin
NPI 1982675864
$2,123.69
in general payments reported to CMS, 2019-2025
35 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $234 · 2021: $480 · 2022: $150 · 2023: $254 · 2024: $427 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.12 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $372.79 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $202.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $173.42 | 2019-2021 | |
| Pfizer INC. | $163.66 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.08 | 2020-2025 | Jardiance |
| Lundbeck LLC | $141.22 | 2024-2025 | Vyepti, Rexulti |
| Exact Sciences Corporation | $85.78 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $61.59 | 2019-2024 | Evenity |
| Abbvie INC. | $56.76 | 2022-2025 | |
| Abbott Laboratories | $56.15 | 2021-2024 | Freestyle Libre 3 |
| Genentech USA, INC. | $47.88 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.78 | 2024-2025 | |
| Astellas Pharma US INC | $45.12 | 2023-2024 | Veozah |
| Vyera Pharmaceuticals, LLC | $44.20 | 2021 | |
| Sumitomo Pharma America, INC. | $44.20 | 2023 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $37.41 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.70 | 2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $33.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.76 | 2019-2020 | |
| Mylan Specialty L.P. | $29.42 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $26.83 | 2021 | |
| Seqirus USA INC | $24.05 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Neurocrine Biosciences, INC. | $22.57 | 2024 | Ingrezza |
| Grifols USA, LLC | $22.30 | 2020 | |
| Nevro Corp. | $21.82 | 2024 | Senza |
| Csl Behring | $17.90 | 2019 | |
| Acadia Pharmaceuticals INC | $17.89 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.71 | 2025 | Caplyta |
| Eisai INC. | $14.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2022 | |
| Sanofi Pasteur INC. | $13.39 | 2023 | |
| Braintree Laboratories, INC. | $13.30 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.98 | 2021 | |
| Glaxosmithkline, LLC. | $12.91 | 2020 | |
| Radius Health, INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pechin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.